Jeff Mortier talks about the latest information about the Cancer Payment Reform Bill.
Author: Editor
At the Myeloma 2015 meeting, Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on immunotherapies that are in clinical development for the treatment of multiple myeloma. Novel immune-based combinations that seem particularly noteworthy are discussed. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas, Fayetteville, AR) and Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) on studies involving new tumour biology-guided strategies for treating multiple myeloma (MM). They focus on immune modulators and inhibitors of critical signalling pathways in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses the design and rationale of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey. The MAGIC survey is an evaluation of the heterogeneity of the treatment decisions made by clinicians regarding the need for adjuvant chemotherapy in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Person they are interveiwng, their credentials
Bobbi Buell from onPoint Oncology talks about ICD-10 and what it means to oncology payments
Keith L. Knutson, PhD, Director, Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida Practical Immuno-Oncology 101 for Oncologists & Nurses
Laura Stevens, Program Director for CMMI Come Home Project talks about the Come Home Project and how it works.
Ricky Newton of COA talks about the new COPA program called Community Oncology Pharmacy Association at the COA annual meeting in Orlando, FL.
Ted Okon and Peter Yu, MD discuss new legislative issues associated with oncology for 2015 at the COA annual meeting in Orlando, FL.
Bo Gamble & Carol Murtaugh talk about What does it take to become a Oncology Medical Home at the annual Community Oncology Alliance meeting in Orlando, 2015
On the first day of the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on new approaches for treating multiple myeloma (MM). Topics include early intervention for smoldering MM, treatment strategies for high-risk MM, and novel drugs in clinical development that may improve patient outcomes in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the opportunities at the 14th St. Gallen International Breast Cancer Conference 2015 to develop new guidelines in breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase 2 PALOMA-1 study of the cyclin-dependent kinase 4/6 inhibitor, palbociclib, in combination with letrozole versus letrozole alone as first-line treatment for women with oestrogen receptor-positive (ER+), HER2-negative (HER2-), advanced breast cancer. The addition of palbociclib to letrozole significantly improved progression-free survival in this patient population. A phase 3 trial is in progress. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Kidney Cancer Organization Welcome Lyon Meeting 2015 Carolyn Konosky
Kidney Cancer Meeting Lyon, France 2015: Immunotherapy versus targeted treatments in metastatic renal cell carcinoma:The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I
Kidney Cancer Meeting Lyon, France 2015: Functional imaging in renal cancer: a 10 year history. Tom Powles Barts Cancer Institute ECMC, UCH and Royal Free Hospitals: London Cancer Queen Mary University of London
Kidney Cancer Meeting Lyon, France 2015: Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy
Kidney Cancer Meeting Lyon, France 2015: Will Immunotherapy Marginalise Targeted Therapy to a Salvage Role by 2020? Tim Eisen University of Cambridge
Kidney Cancer Meeting Lyon, France 2015: Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France
Kidney Cancer Meeting Lyon, France 2015: What Have Sequencing Trials Taught Us?
Kidney Cancer Meeting Lyon, France 2015: Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist
Kidney Cancer Meeting Lyon, France 2015: New target:FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute
Kidney Cancer Meeting Lyon, France 2015: 1st line treatment:what has changed in the last 2 years? Martin Gore PhD FRCP Royal Marsden Hospital Institute of Cancer Research London
Kidney Cancer Meeting Lyon, France 2015: LOCAL TREATMENT FOR LUNG ET LIVER METASTASES SURGERY/ABLATION IS THE GOLD STANDARD – Alain Ravaud, MD PhD Bordeaux University Hospital, Bordeaux, France
Kidney Cancer Meeting Lyon, France 2015: Toxicity from Checkpoint Inhibitors James LarkinFRCP PhD
Kidney Cancer Meeting Lyon, France 2015: TKI drug interaction: what else do I need to know for my patient for anti-VEGF? Romano Danesi, MD, PhD Professor of Pharmacology Department of Clinical and Experimental Medicine University of Pisa Medical School, Italy
Kidney Cancer Meeting Lyon, France 2015: Mechanisms and management of hypertension associated with anti-VEGF-treatment Stephane Ederhy Service de Cardiologie Hopital Saint Antoine Paris, France
Kidney Cancer Meeting Lyon, France 2015: Skin Side Effects Associated with Kidney Cancer Treatment Christiane Thallinger, MD University of Vienna, Department of Oncology, General Hospital vienna
Kidney Cancer Meeting Lyon, France 2015: Vaccines for RCC: Rationale and Clinical Update Hans Hammers M.D. / Ph.D. Assistant Professor: Medical Oncology, Chemical Therapeutics Johns Hopkins Kimmel Cancer Center
Kidney Cancer Meeting Lyon, France 2015: New Targets to Reverse VEGF Resistance Prof. Eric Raymond, MD, PhD Head of Medical Oncology UNIL-CHUV Lausanne – Switzerland
Kidney Cancer Meeting Lyon, France 2015: T-Cell Checkpoints in RCC:Musings from a non-immunologist Primo N. Lara, Jr., M.D. Professor of Medicine University of California Davis School of Medicine Associate Director for Translational Research UC Davis Comprehensive Cancer Center Sacramento, CA, USA
Kidney Cancer Meeting Lyon, France 2015: Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON
Kidney Cancer Meeting Lyon, France 2015: Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? The Oncologists view Viktor Grünwald
Kidney Cancer Meeting Lyon, France 2015:Have Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? Axel Bex, The Netherlands Cancer Institute Amsterdam, The Netherlands
Kidney Cancer Meeting Lyon, France 2015: Should we push for even more minimal invasive and conservative approaches in kidney cancer? The view of the medical oncologist. Manuela Schmidinger, Medical University of Vienna Austria
Kidney Cancer Meeting Lyon, France 2015: Should we push even more for minimal invasive and conservative approaches in kidney cancer? Antonio Alcaraz Hospital ClÃnic Barcelona
Kidney Cancer Meeting Lyon, France 2015: Should We Now Biopsy Every Single Renal Tumor Before Treating? Bernard Escudier Institut Gustave Roussy Villejuif, France
Kidney Cancer Meeting Lyon, France 2015: SHOULD WE NOW BIOPSY EVERY SINGLE RENAL TUMOR BEFORE TREATING ? Alessandro VOLPE, M.D. University of Eastern Piedmont – Maggiore della Carità Hospital Novara, Italy
Kidney Cancer Meeting Lyon, France 2015: John Fitzpatrick Tribute: Life in the Fast Lane
Kidney Cancer Meeting Lyon, France 2015: Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology, MD Anderson
Kidney Cancer Meeting Lyon, France 2015: Clinical Relevance of Cancer Gene, James Brugarolas M.D., Ph.D. Kidney Cancer Program Leader Virginia Murchison Linthicum Endowed Scholar Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center
Kidney Cancer Meeting Lyon, France 2015: Tribute to Pieter De Mulder by Hein Van Poppel Professor and Chairman UZ Leuven Adjunct Secretary General EAU. Nephron Sparing SurgeryPast, Present and Future
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges in the manufacture, development and approval of biosimilars for breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses his highlights from the 14th St. Gallen International Breast Cancer Conference 2015. In addition, he provides an update on the novel combination antiemetic, netupitant and palonosetron (NEPA), for the prevention of chemotherapy-induced nausea and vomiting, and prospective opportunities and challenges for managing breast cancers with a focus on adjuvant therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) discusses the importance of the new therapeutic targets of BCL-2, BH3 mimetics, in oestrogen receptor-positive (ER+) breast cancer, including the challenges in the development process and use in clinical practice. Preclinical models of ER+ breast cancer demonstrate that BH3 mimetics combined with tamoxifen improves the effectiveness of hormone therapy. Clinical studies of the BH3 mimetic, ABT-199, are beginning in ER+ breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the current state of the biosimilar market as well as future challenges of the development and regulation of biosimilars. Biosimilars, which are biological products that demonstrate no clinically meaningful differences to an approved biological product, are currently approved in several areas of the world, and the biosimilars development pipeline is relatively large.European Medical JournalWebsite: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
This is my interview with Jeri Francoeur, Breast Cancer Patient Advocate, breast cancer survivor, and President of the Susan G Komen Chapter in Central Florida.
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin-dependent kinases (CDKs) 4 and 6 inhibitor, palbociclib, for breast cancer treatment. The phase 2 PALOMA-1 trial showed that the addition of palbociclib to letrozole significantly increased the progression-free survival versus letrozole alone in oestrogen receptor-positive, HER2-negative metastatic breast cancer. Subsequently, palbociclib received accelerated approval as frontline treatment for this patient population. Current trials are investigating palbociclib in other areas of breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 14th St. Gallen International Breast Cancer Conference (SG-BCC) 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how mining big data can complement research approaches and improve patient care in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews